$0.18
▲ +1.5% Today
as of Sep 4, 16:49 ET
Last 30 days
Recent Press Releases & News
Gossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?
Gossamer Bio announces $250m in funding to advance seralutinib
Overview
52-week range
$0.11
$3.87
2% of range
Avg surprise (last 3)
-0.3%
Avg reaction (last 2)
+3.5%
100% positive
Latest IV / EM
2311%
EM ±373.8% · $1 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.08 | — | — | — | — | financials |
| Fri May 15, 2026 | Mar/2026 | $-0.20 | $-0.17 | -17.6% | -25.0% | +3.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.21 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.17 | $-0.18 | +5.6% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.16 | $-0.18 | +11.1% | — | +4.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.14 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.22 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.19 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.21 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.45 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.52 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9M | $17M | — | $13M | $11M | $10M | — | $9M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-26M | $-45M | — | $-49M | $-39M | $-37M | — | $-34M |
| Net income | $17M | $-47M | — | $-48M | $-38M | $-37M | — | $-31M |
| EPS (diluted) | $-0.08 | $-0.20 | — | $-0.21 | $-0.17 | $-0.16 | — | $-0.14 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $41M | $41M | $38M | $9M | $26M | $29M | $46M | $28M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $73M | $125M | $168M | $204M | $236M | $275M | $310M | $344M |
| Total assets | $77M | $129M | $172M | $209M | $241M | $281M | $315M | $351M |
| Long-term debt | — | — | — | — | — | — | — | $0 |
| Total liabilities | $171M | $290M | $295M | $291M | $287M | $287M | $286M | $297M |
| Total equity | $-94M | $-161M | $-123M | $-82M | $-46M | $-6M | $29M | $54M |